Arrowhead Pharmaceuticals, Inc. (ARWR)
Largest Insider Buys in Sector
ARWR Stock Price History Chart
ARWR Stock Performance
About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in …
Insider Activity of Arrowhead Pharmaceuticals, Inc.
Over the last 12 months, insiders at Arrowhead Pharmaceuticals, Inc. have bought $82,990 and sold $9.12M worth of Arrowhead Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Arrowhead Pharmaceuticals, Inc. have bought $103,722 and sold $24.69M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Lu Hongbo (director) — $165,980.
The last purchase of 1,000 shares for transaction amount of $27,500 was made by Lu Hongbo (director) on 2024‑03‑20.
List of Insider Buy and Sell Transactions, Arrowhead Pharmaceuticals, Inc.
| 2024-07-02 | Sale | Chief Commercial Officer | 9,394 0.0073% | $25.28 | $237,480 | 0.00% | ||
| 2024-05-02 | Sale | director | 1,799 0.0014% | $23.31 | $41,935 | -0.87% | ||
| 2024-04-01 | Sale | Chief Discovery/Trans Medicine | 6,000 0.0048% | $28.03 | $168,180 | -15.30% | ||
| 2024-03-20 | director | 1,000 0.0008% | $27.50 | $27,500 | -14.84% | |||
| 2024-03-19 | director | 1,000 0.0008% | $28.00 | $28,000 | -13.52% | |||
| 2024-03-18 | director | 1,000 0.0008% | $27.49 | $27,490 | -14.65% | |||
| 2024-03-06 | Sale | Chief Financial Officer | 40,000 0.0323% | $35.19 | $1.41M | -31.04% | ||
| 2024-01-31 | Sale | Chief Executive Officer | 57,499 0.0525% | $32.35 | $1.86M | -22.49% | ||
| 2024-01-12 | Sale | Chief Discovery/Trans Medicine | 7,940 0.0075% | $36.89 | $292,904 | -31.33% | ||
| 2024-01-11 | Sale | director | 2,911 0.0028% | $38.06 | $110,788 | -33.26% | ||
| 2024-01-11 | Sale | director | 3,147 0.003% | $38.06 | $119,787 | -33.26% | ||
| 2024-01-11 | Sale | director | 3,934 0.0037% | $38.07 | $149,759 | -33.26% | ||
| 2024-01-11 | Sale | director | 4,720 0.0045% | $38.10 | $179,813 | -33.26% | ||
| 2024-01-05 | Sale | COO and General Counsel | 22,841 0.021% | $35.27 | $805,716 | -29.57% | ||
| 2024-01-05 | Sale | Chief Financial Officer | 16,104 0.0148% | $35.27 | $567,910 | -29.57% | ||
| 2024-01-05 | Sale | 32,143 0.0295% | $35.18 | $1.13M | -29.57% | |||
| 2024-01-05 | Sale | Chief Medical Officer | 8,303 0.0076% | $35.26 | $292,804 | -29.57% | ||
| 2024-01-05 | Sale | Chief Commercial Officer | 74 <0.0001% | $33.89 | $2,508 | -29.57% | ||
| 2024-01-04 | Sale | COO and General Counsel | 1,600 0.0014% | $32.63 | $52,208 | -26.58% | ||
| 2024-01-03 | Sale | COO and General Counsel | 8,749 0.0082% | $32.28 | $282,439 | -20.16% |
Insider Historical Profitability
| Anzalone Christopher Richard | Chief Executive Officer | 3715048 2.9884% | $21.34 | 4 | 35 | <0.0001% |
| Myszkowski Kenneth Allen | Chief Financial Officer | 400600 0.3222% | $21.34 | 1 | 27 | <0.0001% |
| GIVEN DOUGLAS B | director | 129711 0.1043% | $21.34 | 1 | 19 | <0.0001% |
| Ferrari Mauro | director | 60778 0.0489% | $21.34 | 2 | 4 | +71% |
| Lu Hongbo | director | 33680 0.0271% | $21.34 | 3 | 0 |
Institutional Investor Ownership
| BlackRock | $438.91M | 12.36 | 15.35M | +15.36% | +$58.43M | 0.01 | |
| The Vanguard Group | $354.76M | 9.99 | 12.4M | +16.23% | +$49.53M | 0.01 | |
| Avoro Capital Advisors Llc | $244.69M | 6.89 | 8.56M | +657.13% | +$212.37M | 2.93 | |
| State Street | $187.64M | 5.28 | 6.56M | -3.87% | -$7.56M | 0.01 | |
| Fidelity Investments | $182.89M | 5.15 | 6.39M | +89.68% | +$86.47M | 0.01 |